COMMUNIQUÉS West-GlobeNewswire

Solon Eiendom ASA – Primary insider notification

06/09/2018 - 08:30

(Oslo, Norway, September 5, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 5.000 shares in Solon Eiendom ASA at a price of NOK 28.0933. Following this [...]

Shire plc: Rule 2.9 Announcement

06/09/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 September 2018 [...]

Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal

06/09/2018 - 08:00

Publication demonstrates RPL554’s significant bronchodilation effect, in both large and small airways, alone and when combined with currently used bronchodilators in COPD patients LONDON, Sept. 06, 2018 (GLOBE NEWSWIRE [...]

Nicox annonce son intention de réaliser une offre sous prospectus d'American Depository Shares au NASDAQ aux Etats-Unis

06/09/2018 - 07:31

Communiqué de presse Nicox annonce son intention de réaliser une offre sous prospectus d'American Depository Shares au NASDAQ aux Etats-Unis ................................................. 6 septembre 2018 - diffusion [...]

FIT Biotech Oy: FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2018

06/09/2018 - 07:31

FIT Biotech Oy Company release 6.9.2018 at 8:30 EET FIT BIOTECH OY HALF-YEARLY FINANCIAL REPORT JANUARY 1 - JUNE 30, 2018 Unaudited This company release is a summary of FIT Biotech's Half-yearly Financial Report January [...]

Nicox First Half 2018 Financial Results and Business Update

06/09/2018 - 07:31

Press Release Nicox First Half 2018 Financial Results and Business Update ................................................. NCX 470 Phase 2 clinical study initiated in Q3 2018 NCX 4251 on track for U.S. IND filing in Q1 [...]

Nicox : Résultats financiers du premier semestre 2018 et point des activités

06/09/2018 - 07:31

Communiqué de presse Nicox : Résultats financiers du premier semestre 2018 et point des activités ................................................. NCX 470 : Initiation d'une étude clinique de phase 2 au troisième [...]

Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States

06/09/2018 - 07:31

Press Release Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States ................................................. September 6, 2018 - release at 7:30 am CET Sophia Antipolis, [...]

Sensorion Presents Three Posters At The 55th Inner Ear Biology Workshop

06/09/2018 - 07:30

MONTPELLIER, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases, today presented three posters at the 55 th Inner Ear [...]

Nicox Announces Intention to Conduct a Registered Offering on NASDAQ in the United States

06/09/2018 - 07:30

SOPHIA ANTIPOLIS, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmic company, announced today that it has previously confidentially submitted a draft [...]

ERYTECH to Host Second Quarter 2018 Conference Call and Business Update

06/09/2018 - 07:30

LYON, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug [...]

ERYTECH tiendra un webcast le 11 septembre 2018 à l’occasion de ses résultats semestriels 2018

06/09/2018 - 07:30

LYON, France, 06 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans [...]

Nicox First Half 2018 Financial Results and Business Update

06/09/2018 - 07:30

NCX 470 Phase 2 clinical study initiated in Q3 2018 NCX 4251 on track for U.S. IND filing in Q1 2019 to enable first-in-human Phase 2 clinical study SOPHIA ANTIPOLIS, France, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Nicox SA [...]

GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT

06/09/2018 - 07:01

Foster City, Calif. and Mechelen, Belgium; September 6, 2018; 7.00 CET; Regulated information - Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the randomized, [...]

Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2018 RESULTS

06/09/2018 - 07:01

PRESS RELEASE : REGULATED INFORMATION Thursday, 6 September 2018, 07:00 CEST BIOCARTIS ANNOUNCES H1 2018 RESULTS Mechelen, Belgium , 6 September 2018 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]

Kiadis Pharma announces two senior management appointments

06/09/2018 - 07:01

Kiadis Pharma announces two senior management appointments Strengthens Senior Management Team with Chief Human Resources Officer and General Counsel and Company Secretary Amsterdam, The Netherlands, September 6, 2018 - [...]

argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

06/09/2018 - 07:01

September 6, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

06/09/2018 - 04:31

Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic oral solids and Sandoz US [...]

Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering

06/09/2018 - 02:32

SAN DIEGO, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes [...]